U.S., June 30 -- ClinicalTrials.gov registry received information related to the study (NCT07674693) titled 'Phase 1 Study of WBRT or PCSI With REYOBIQ for Leptomeningeal Metastases' on June 18.
Brief Summary: This Phase 1 study is designed to assess the safety, tolerability, and schedule feasibility of administering Rhenium-186 NanoLiposome (REYOBIQ) at different dosing intervals following whole brain radiotherapy (WBRT) or proton craniospinal irradiation (PCSI).
Study Start Date: July, 2026
Study Type: INTERVENTIONAL
Condition:
Leptomeningeal Metastases
Intervention:
DRUG: 186RNL
Intraventricular injection via catheter. Patients will be assigned to three separate dosing schedules and once assigned they will remain on that dose lev...